Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - ZIOPHARM ONCOLOGY INC | v242547_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 7, 2011
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
001-33038
|
84-1475672
|
||
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
1180 Avenue of the Americas
19th Floor
New York, NY
|
10036
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(646) 214-0700
(Registrant’s telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
|
|
Item 8.01
|
Other Events
|
On December 7, 2011, the Company issued a press release announcing that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled “Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents” with claims directed to pharmaceutical compositions of a novel DNA cross-linker (stabilized active metabolite of ifosfamide), including palifosfamide (Zymafos® or ZIO-201) and their use in treating cancer.
A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report of Form 8-K.
|
Financial Statements and Exhibits
|
|||
|
(d)
|
Exhibits
|
||
|
Exhibit No.
|
Description
|
||
|
99.1
|
Press Release of the Company dated December 7, 2011
|
||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ZIOPHARM Oncology, Inc.
|
||
|
By:
|
/s/ Caesar Belbel
|
|
|
Date: December 7, 2011
|
Name: Caesar Belbel
|
|
|
Title: Executive Vice President, Chief Legal Officer and Secretary
|
||
3
INDEX OF EXHIBITS
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release of the Company dated December 7, 2011
|
|
4